Introduction
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with multiple myeloma (MM), resulting in higher response and survival rates than conventional chemotherapy. 1, 2 Given the potential benefits of auto-HSCT, successful stem cell mobilization and collection are crucial, as is an understanding of the impact that an induction regimen may have on this process.
Over the past few years, the regimens for treatment of MM have changed with the availability of new, highly effective agents. In newly diagnosed patients, the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, have increased response rates in comparison with the response rates of standard induction therapy. 3, 4 Lenalidomide is a less toxic analog of thalidomide that, when used in combination with dexamethasone, has been shown to be superior in efficacy to dexamethasone alone in patients with relapsed and refractory MM. 5, 6 High activity of this combination has been observed in patients with newly diagnosed MM, and preliminary phase 3 data are very promising. [7] [8] [9] [10] The growing use of these new agents has raised questions about the role and timing of high-dose chemotherapy and auto-HSCT in the treatment of MM, but experts agree that this approach will likely remain an important part of both firstline and salvage therapy. 11 Optimal stem cell collection is an important element of the myeloma treatment strategy, allowing auto-HSCT in either early or later stages of disease. 11 Although lenalidomide is a promising treatment for newly diagnosed patients, it can impair subsequent stem cell mobilization and collection both in frontline and salvage settings. [12] [13] [14] [15] [16] [17] Mobilization failure rates ranging from 7 to 77% (target CD34 þ cell yields ranged from 2 Â 10 6 to 4 Â 10 6 per kg) have been reported among patients previously treated with lenalidomide, primarily among those who had received cytokine-only mobilization.
12-17 Therefore, should there be a significant increase in the number of patients receiving early therapy with lenalidomide, more patients may experience poor or failed stem cell mobilization in the future.
Plerixafor (Mozobil) is a novel, small-molecule bicyclam derivative approved for use with G-CSF to mobilize stem cells for autologous transplantation in patients with MM or non-Hodgkin's lymphoma. 18 Plerixafor selectively and reversibly binds to the chemokine receptor CXCR4 and blocks its interaction with stromal cell-derived factor-1a, thereby releasing stem cells from the BM into the peripheral blood. 19 Plerixafor has been shown to be effective for initial mobilization of CD34 þ cells in patients with MM who are eligible for auto-HSCT. 20 In a phase 3 study, a significantly higher proportion of patients with MM reached the optimal target of X6 Â 10 6 CD34 þ cells per kg in 2 or fewer days of apheresis with plerixafor plus G-CSF (71.6%) than with placebo plus G-CSF (34.4%, Po0.001). In addition to its use for primary mobilization, a regimen of plerixafor plus G-CSF is also effective when previous mobilization attempts have failed 21, 22 and when poor mobilization is predicted. 23 The purpose of this retrospective analysis is to examine the efficacy of plerixafor in combination with G-CSF when used both for frontline mobilization and for remobilization among patients who were previously treated with lenalidomide.
Materials and methods

Data sources
This retrospective analysis of patients with MM who received plerixafor plus G-CSF for mobilizing stem cells used four data sources: (1) a phase 3 study of plerixafor plus G-CSF (Study 3102); 20 (2) the North American expanded access program (EAP); (3) a European phase 3 safety study (referred to as PREDICT) and (4) the US compassionate use program (CUP). 21 Patients in Study 3102, the EAP and the PREDICT study underwent frontline mobilization, whereas patients enrolled in the CUP underwent remobilization after failure of previous mobilization attempts. Completion of case report forms for the CUP and submissions to the sponsor were tracked through telephone and written contact with the site. Patients were included in this analysis only when complete data were available on the number of lenalidomide cycles administered and the total number of CD34 þ cells collected. Data were analyzed for all patients as well as for patients grouped according to whether they received plerixafor plus G-CSF for frontline mobilization (Group A) or remobilization (Group B).
Assessments
For this analysis, the primary end point was the proportion of patients from whom X2 Â 10 6 CD34 þ cells per kg were mobilized. Other end points were the proportion of patients from whom X5 Â 10 6 CD34 þ cells per kg were mobilized and the time to engraftment. Neutrophil engraftment was defined as the first of 3 consecutive days with an ANC X0.5 Â 10 9 per L or 1 day with a count of X1.0 Â 10 9 per L. Plt engraftment was defined as the first day that a plt count of X20 Â 10 9 per L was reached, as measured by X3 consecutive plt laboratory values obtained over X7 days without transfusion support.
Inclusion criteria
For inclusion in Study 3102, patients were required to have a biopsy-confirmed diagnosis of MM in first or second complete or PR with planned single or tandem auto-HSCT. 20 Patients with a diagnosis of MM, non-Hodgkin's lymphoma or Hodgkin's disease who were eligible for auto-HSCT were enrolled in the EAP, the PREDICT study and the CUP, but only data from MM patients were used in this analysis. Patients in the CUP must have experienced failed mobilization with conventional therapies (usually collection of o2 Â 10 6 CD34 þ cells per kg) or, in the opinion of the treating physician, were not likely to experience a successful mobilization because of low peripheral CD34 þ cell counts (usually o10 per mL).
All patients were required to be from 18 to 78 years of age (there was no upper age limit in the EAP or the PREDICT study) and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Additional inclusion criteria were WBC count 42.5 Â 10 9 per L; ANC 41.5 Â 10 9 per L; plt count 485 Â 10 9 per L in the CUP and 4100 Â 10 9 per L in Study 3102, the EAP and the PREDICT study; normal renal and hepatic function; and adequate cardiac and pulmonary function.
Exclusion criteria
Patients were excluded from all protocols if they had plasma cell leukemia, any comorbid condition that placed them at high risk for complications, central nervous system involvement, clinically significant heart disease, HIV infection, active infection or fever. Patients in whom a previous stem cell mobilization attempt had failed were not eligible for Study 3102, the EAP or the PREDICT study. Additional exclusion criteria for Study 3102, the EAP and the PREDICT study were chemotherapy within 4 weeks of mobilization; treatment with a nitrosourea (for example, carmustine) within 6 weeks of mobilization; treatment with thalidomide, lenalidomide, dexamethasone and/or bortezomib within 1 week of mobilization; or treatment with a cytokine within 2-3 weeks of mobilization.
Mobilization protocol
The mobilization protocol consisted of G-CSF 10 mg/kg/ day s.c. on days 1-4 ( Figure 1 ). On the evening of day 4, patients began receiving plerixafor 0.24 mg/kg/day s.c., and apheresis was initiated approximately 10 h later on the morning of day 5. Daily administration of G-CSF before apheresis in the morning and of plerixafor in the evening continued until the target number of CD34 þ cells was collected or until a predetermined maximum number of aphereses was reached. In Study 3102 and for patients with MM in the EAP and the PREDICT study, the protocol continued either until the target of X6 Â 10 6 CD34 þ cells per kg was reached or for a maximum of 4 (Study 3102) or 5 (EAP and PREDICT) aphereses. In the CUP, patients with MM continued the protocol until X2 Â 10 6 CD34 þ cells per kg were collected. Following mobilization, patients received myeloablative conditioning and then proceeded to auto-HSCT. For patients enrolled in Study 3102, the EAP and the PREDICT study, a 3 Â blood volume apheresis was recommended. For patients in the CUP, apheresis was performed as per standard institution practices.
Results
Efficacy
Complete data on the number of cycles of lenalidomide and total number of CD34 þ cells collected were available for 60 patients: 5 patients from Study 3102, 14 patients from the EAP, 1 patient from the PREDICT study and 40 patients from the CUP. There was a higher proportion of men in Group A (Study 3102, EAP and PREDICT) than in Group B (CUP), and patients in Group A had received fewer cycles of lenalidomide than patients in Group B (medians, 3.5 vs 4.0 cycles, P ¼ 0.025) ( Table 1) . For the entire cohort, the median age at mobilization was 60 years, 54.2% of patients were men, and a median of 4 cycles (range, 1-20 cycles) of lenalidomide had been received. The majority of patients were classified as Caucasian.
The overall median number of CD34 þ cells collected was 5.6 Â 10 6 per kg (range, 0.45 Â 10 6 -37.2 Â 10 6 per kg) ( Table 2) Because cumulative exposure to lenalidomide may have deleterious effects on the ability to mobilize stem cells, the proportion of patients who were able to mobilize the minimum number of CD34 þ cells was analyzed on the basis of the number of prior lenalidomide cycles (Table 3) . In Group A, all patients collected the minimum number of CD34 þ cells per kg, regardless of the number of previous cycles of lenalidomide they had received. In Group B, all 11 patients who had received p3 cycles of lenalidomide and 21 of 29 patients (72%) who had received 43 cycles of lenalidomide reached the minimum number of CD34 þ Figure 1 Depicts details of mobilization and apheresis periods. cells per kg. Furthermore, the minimum number of CD34 þ cells per kg was collected from 29 of 36 patients (81%) who received p6 cycles of lenalidomide and 3 of 4 patients (75%) who received 46 cycles of lenalidomide. Overall, 54 of 60 patients (90.0%) proceeded to transplantation. Although the minimum number of CD34 þ cells was not collected in eight patients in Group B, two of these patients were able to proceed to transplantation: one patient was transfused with 1.9 Â 10 6 CD34 þ cells per kg and the other was transfused with pooled cells. Of the six patients not proceeding to transplantation, the median yield was 0.85 Â 10 6 CD34 þ cells per kg, the median age was 64.5 years and the median cycles of lenalidomide received was 5.5 (range, 4-20 cycles). The median time to neutrophil and plt engraftment was 12 days (range, 10-20 days) and 18 days (range, 7-66 days), respectively.
Discussion
In this retrospective analysis, stem cells could be predictably and successfully mobilized with plerixafor plus G-CSF in the majority of patients with MM who had been pretreated with lenalidomide. Plerixafor plus G-CSF mobilized the minimal and optimal CD34 þ cell dose in 86.7 and 63.3% of lenalidomide-pretreated MM patients, respectively. Median time to engraftment of neutrophils and plts was 12 and 18 days, respectively. Frontline mobilization with plerixafor plus G-CSF resulted in collection of X2 Â 10 6 and X5 Â 10 6 CD34 þ cells per kg in 100.0 and 95.0% of patients, respectively, indicating that plerixafor plus G-CSF is highly effective in this setting. Among patients in whom a previous mobilization attempt had failed, remobilization with plerixafor plus G-CSF allowed collection of X2 Â 10 6 CD34 þ cells per kg in 80.0% of patients, and although not a target end point for the CUP study, collection of X5 Â 10 6 CD34 þ cells per kg was possible in 47.5% of patients. The lower rate of successful mobilization may be explained by higher risk for failure of mobilization inherent in this population, most likely due to more extensive previous therapies and therefore more advanced disease.
Mobilization failure rates in patients pretreated with lenalidomide range from 7 to 77%.
12,14-17 Kumar et al. 12 reported that 7% of patients undergoing mobilization with G-CSF alone (10-32 mg/kg/day) did not proceed to collection because of low peripheral blood CD34 þ cell counts (o10 per mL). Popat et al. 17 recently reported a mobilization failure (o2 Â 10 6 CD34 þ cells per kg) rate of 25% with G-CSF alone in patients who had previously received lenalidomide. In a case series, mobilization with G-CSF (10 mg/kg/day) alone or G-CSF (7.5 mg/kg/day) plus GM-CSF (7.5 mg/kg/day) failed to yield X2 Â 10 6 CD34 þ cells per kg in 43% of patients. 15 In another retrospective analysis, the target of 42 Â 10 6 CD34 þ cells per kg was not reached with G-CSF (10 mg/kg/day) alone in 45% of patients. 16 A relatively high mobilization failure rate was observed in a study by Mark et al., 14 wherein G-CSF (10 mg/kg/day) alone failed to mobilize X4 Â 10 6 CD34 þ cells per kg in 77% of patients, and no association was found between the number of lenalidomide cycles received and mobilization success. In the experience reported here, the combination of G-CSF and plerixafor resulted in Table 2 Stem cell collection in patients previously treated with lenalidomide
All patients (N ¼ 60) relatively low failure rates ranging from 0% in patients receiving this regimen for frontline mobilization to 20% in patients undergoing remobilization. Studies that have examined the impact of duration or number of cycles of lenalidomide therapy on stem cell yields have given mixed results. 12, 13, 16, 17 In our analysis (Table 3) , all patients undergoing frontline mobilization with plerixafor plus G-CSF reached collection of X2 Â 10 6 CD34 þ cells per kg irrespective of whether they had received p3 or 43 cycles of lenalidomide. In patients undergoing remobilization, all patients with p3 cycles of lenalidomide and the majority of patients (72%) with 43 cycles of lenalidomide had collections of the minimal cell dose. Comparison of the mobilization success rates between patients who received 46 or p6 cycles of lenalidomide does not yield meaningful conclusions because very few patients in Group A (n ¼ 1) or Group B (n ¼ 4) had received 46 cycles.
Chemotherapy with G-CSF has been shown to be effective for primary mobilization or remobilization of stem cells in patients who have been treated with lenalidomide.
14,17 However, chemotherapy-based mobilization is associated with increased toxicity, prolonged collection and increased resource use. [24] [25] [26] [27] [28] Furthermore, the addition of chemotherapy to G-CSF for the purpose of stem cell mobilization does not add to the therapeutic effect for MM in terms of response rate and long-term clinical outcomes. 29 In various clinical trials, plerixafor has shown synergy with G-CSF for mobilizing stem cells in patients with MM, 19, 20, 30 including those in whom other mobilization attempts have failed, 21, 22 those who have been heavily pretreated with chemotherapy, 31 and those who are predicted to experience poor mobilization. 23 In a CUP cohort of 35 MM patients in whom mobilization had previously failed or was predicted to fail, plerixafor plus G-CSF successfully remobilized stem cells in 71% of patients, with 77% of patients proceeding to transplantation. 21 Stiff et al. 31 found that 67% of heavily pretreated lymphoma and MM patients who received plerixafor plus G-CSF for frontline mobilization reached the target of X5 Â 10 6 CD34 þ cells per kg, and all patients reached the yield required to proceed with transplantation. Risk factors such as age greater than 60 years, extent of prior chemotherapy or radiotherapy and prolonged disease duration are recognized as indicators that predict poor mobilization.
11
As such, a recently published consensus statement from the International Myeloma Working Group recognizes frontline use of plerixafor as a strategy to overcome poor mobilization in patients with these risk factors. 11 Another recent International Myeloma Working Group statement recommends early collection of stem cells in patients with previous exposure to lenalidomide; collection within the first 4 cycles is advised. 27 Our data indicate that plerixafor plus G-CSF is an effective mobilization strategy in patients with MM who have been treated with lenalidomide. The safety of plerixafor as a hematopoietic stem cell mobilizing agent has been shown in various clinical trials. [19] [20] [21] [22] 31 This was a retrospective analysis of data from patients with previous exposure to lenalidomide. A limitation of this analysis is that most of the data were derived from patients enrolled in the CUP who, by definition, are at a higher risk of mobilization failure. Thus, the relative contribution of lenalidomide treatment to poor stem cell yields in these patients could not be definitively evaluated. Furthermore, data on concurrent therapies patients received in addition to lenalidomide were not available for this analysis. Some patients, particularly those enrolled in the CUP, were treated with multiple lines of therapy, which may have contributed to the mobilization failures in that group. The interaction of lenalidomide exposure with other pretransplant risk factors for suboptimal mobilization should be explored, as well as the duration of lenalidomide therapy, the dose and the length of time between the last dose and mobilization.
In conclusion, this retrospective analysis has shown that the majority of patients with MM who have been exposed to lenalidomide undergo successful stem cell mobilization with a regimen of plerixafor plus G-CSF. Prospectively designed studies evaluating the efficacy of plerixafor exclusively for frontline mobilization in lenalidomide-treated patients are under way and should prove informative.
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